Key pipeline programs include WVE-006 for alpha-1 antitrypsin deficiency, WVE-007 targeting obesity, WVE-N531 for Duchenne muscular dystrophy, and WVE-003 for Huntington's disease. The company is accelerating development of WVE-007 for obesity and advancing an RNA editing portfolio as strategic 2026 priorities.
Cyborg Score Rationale
Analyst sentiment is overwhelmingly positive with 15 buy ratings and no hold or sell ratings. However, the company exhibits typical clinical-stage biotech financials with forward P/E of -10.91 and negative free cash flow of -$147.7 million.
Top Insights
Market capitalization of approximately $2.99 billion reflects substantial biotech industry presence
Positive interim Phase 1 data from INLIGHT trial showed WVE-007 improved body composition with fat loss similar to GLP-1 at three months without muscle loss
Analyst average target price of $30.53 indicates significant growth potential with target range between $21.00 and $50.00
Company operates across Singapore, US, Japan, UK, and Ireland providing global research and development capabilities
Named Competitors
Arrowhead Therapeutics — RNA therapeutics for rare and common diseases